Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

Ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) showed clinical efficacy over placebo-Rd in patients with relapsed/refractory multiple myeloma (MM) in the TOURMALINE-MM1 trial. Over a median follow-up of ∼85 months, as patients showed disease progression, they received subsequent novel therapies that confounded the overall survival (OS) benefit. Here, we conducted a post hoc analysis in 148 patients from seven countries defined as emerging markets, with limited access to novel therapies for MM during the trial period, to describe the impact of these therapies on OS. Patients were randomised to ixazomib-Rd (

Informations de copyright

© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

Nakul Saxena is an employee of Takeda Pharmaceuticals International AG, Singapore and holds stocks of Takeda Pharmaceuticals. Kwang‐Wei Wu was an employee of Takeda Pharmaceuticals International AG, Singapore, during the conduct of this study and holds stocks of Takeda Pharmaceuticals. Her present affiliation is Janssen Pharmaceuticals (as of February 2022). Richard Labotka and Cong Li are employees of Takeda Development Center America and hold stocks of Takeda Pharmaceuticals. Meral Beksac has received honoraria from Amgen, Janssen, Sanofi, Oncopeptides, Celgene and Takeda. Andrew Spencer, Olga Samoilova, Wee‐Joo Chng, Xu Yan and Jae Hoon Lee state no conflict of interest.